(MedPage Today) — If therapies were to expand to people with mild hypertrophic cardiomyopathy (HCM), the first in line should be specific groups more prone to disease worsening, suggested one registry study. Out of 2,500 people with phenotypically…
Source: MedPage Today — Headlines
